NEWS

PRESS RELEASES

Exciting things are happening at Greenwich Biosciences. Here is the latest news about our company, products, and pipeline.

Scroll Arrow Icon

Greenwich Biosciences, Inc. is the US subsidiary of GW Pharmaceuticals plc. For general corporate information, please click here.

May 6, 2019
Greenwich Biosciences Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution CV in Patients with Seizures Associated With Tuberous Sclerosis Complex
Read More
May 2, 2019
Greenwich Biosciences to Present Data on FDA-approved EPIDIOLEX® (cannabidiol) Oral Solution CV at the 2019 American Academy of Neurology Annual Meeting
Read More
Nov 27, 2018
Company Announces Results from Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) Oral Solution CV in Patients with Dravet Syndrome
Read More
Nov 19, 2018
Greenwich Biosciences to Present New Data on FDA-approved EPIDIOLEX® (cannabidiol) Oral Solution CV at the American Epilepsy Society Annual Meeting
Read More
Nov 1, 2018
EPIDIOLEX® (cannabidiol) Oral Solution CV – the First FDA-approved Plant-derived Cannabinoid Medicine – Now Available by Prescription in the U.S.
Read More
Jun 25, 2018
Greenwich Biosciences Announces FDA Approval of EPIDIOLEX® (cannabidiol) Oral Solution CV - the First Plant-derived Cannabinoid Prescription Medicine
Read More
   
 
 
 

INVESTORS

For investor inquiries and media, please contact:

Stephen Schultz
Vice President, Investor Relations
917.280.2424 Tel.
760.795.2219 Fax
Email

 

Christy Curran
Sam Brown Inc.
615-414-8668 Tel.
Email

Scroll Arrow Icon

Spotlight Articles

Exciting things are happening at Greenwich Biosciences. View the latest news about our company, products, and pipeline.

View

Media Library

Explore helpful downloads and information.

View